Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD40 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD40 ECD-Fc Fusion Protein (Human/Mouse/Cyno) High purity (>95%), HEK293 Expressed (Native Glycosylation). Endotoxin <1EU/µg. Sequence Verified by Mass Spec. |
View CD40 Products |
| Gene Delivery | CD40 Lentivirus Premade Particles Full-length ORF for stable cell line generation (Reporter assays). |
View CD40 Products |
| Benchmark Ab (Agonist) | Anti-CD40 (Sotigalimab Biosimilar Sequence) Recombinant agonistic positive control, IgG1 format. |
View CD40 Products |
| Benchmark Ab (Antagonist) | Anti-CD40 (Lucatumumab Biosimilar Sequence) Recombinant antagonistic control, blocks CD40L binding. |
View CD40 Products |
| Validator | CD40 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View CD40 Products |
| Related Target: CD40L | CD154 (CD40 Ligand) Natural receptor counterpart; critical for antagonist screening. |
View CD40L Products |
| Related Target: FcγRIIB | CD32b (FcγRIIB) Fc receptor for crosslinking assays; determines agonist potency. |
View FCGR2B Products |
| Related Target: CD27 | CD27 (TNFRSF7) Alternative co-stimulatory target; combination therapy potential. |
View CD27 Products |
| Related Target: 4-1BB | TNFRSF9 (4-1BB) TNF receptor superfamily member for selectivity counter-screening and immuno-oncology synergy. |
View TNFRSF9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (cyno/mouse) | Human/Mouse/Cyno CD40 ortholog proteins available with >95% purity; sequence verified by mass spectrometry. |
| FcγRIIB-dependent Agonism Screening | High-purity CD40 ECD + FcγRIIB recombinant proteins for in vitro crosslinking assays; native glycosylation preserved (HEK293). |
| Agonist vs. Antagonist Epitope Mapping | Benchmark antibody pairs (Agonist/Antagonist) included; CD40L blocking assay ready. |
| Reporter Cell Line Construction | Lentivirus particles with Puromycin selection marker; ready for NF-κB reporter stable cell generation. |
| TNFRSF subfamily off-target safety | Homolog panel proteins (CD95, DR4, DR5, TNFR1, OX40, 4-1BB) strictly verified by MS for selective binding ELISA/SPR. |
| Assay specificity & false positives | CD40-targeted siRNA included for knockdown confirmation in NF-κB reporter and flow cytometry assays. |
Live CD40 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (CD40 Agonists)
- ➤ View Active Clinical Trials (CD40 Antagonists)
- ➤ Latest Resistance & Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The CD40 therapeutic landscape is bifurcating into two major fronts: immuno-oncology (IO) agonists and autoimmune antagonists. First-generation systemic agonists (e.g., Sotigalimab) faced dose-limiting toxicities including cytokine release syndrome and hepatotoxicity, catalyzing a strategic shift toward conditional activation strategies. The next wave of R&D focuses on Fc-engineered variants with optimized FcγRIIB engagement, masked antibodies activated by tumor microenvironment proteases, and tumor-targeted bispecifics (e.g., CD40 × FAP). Key players include Apexigen, Alligator Bioscience (mitazalimab), Celldex Therapeutics (CDX-1140) in IO agonists, and Novartis (Iscalimab) and Roche in autoimmune antagonists. Subcutaneous formulations for chronic autoimmune administration are emerging as a key differentiator.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb (Fc-engineered) | Apexigen, Alligator Bioscience, Celldex, Roche | Solid tumors (pancreatic, melanoma, NSCLC) | FcγRIIB Crosslinking Assay (requires high-purity Fc receptor and CD40) |
| Antagonistic mAb | Novartis (Iscalimab), Roche | SLE, Transplant Rejection, Autoimmune Hepatitis | CD40L Blocking Assay (high-affinity ECD-Fc required) |
| Bispecific (CD40 × TAA) | Roche, Genmab, Merus, Emerging biotech | Solid tumors (localized activation) | Cell-Cell Bridging Assay (requires CD40-expressing reporter cells and dual antigens) |
| ADC | Seattle Genetics (legacy), Emerging pipeline | Non-Hodgkin Lymphoma, Hematologic Malignancies | Internalization Assay (need surface-stable CD40 antigen and lentivirus-constructed cell lines) |